Literature DB >> 24349632

Role of p38 MAP Kinase Signal Transduction in Solid Tumors.

Hari K Koul1, Mantu Pal2, Sweaty Koul3.   

Abstract

Mitogen-activated protein kinases (MAPKs) mediate a wide variety of cellular behaviors in response to extracellular stimuli. One of the main subgroups, the p38 MAP kinases, has been implicated in a wide range of complex biologic processes, such as cell proliferation, cell differentiation, cell death, cell migration, and invasion. Dysregulation of p38 MAPK levels in patients are associated with advanced stages and short survival in cancer patients (e.g., prostate, breast, bladder, liver, and lung cancer). p38 MAPK plays a dual role as a regulator of cell death, and it can either mediate cell survival or cell death depending not only on the type of stimulus but also in a cell type specific manner. In addition to modulating cell survival, an essential role of p38 MAPK in modulation of cell migration and invasion offers a distinct opportunity to target this pathway with respect to tumor metastasis. The specific function of p38 MAPK appears to depend not only on the cell type but also on the stimuli and/or the isoform that is activated. p38 MAPK signaling pathway is activated in response to diverse stimuli and mediates its function by components downstream of p38. Extrapolation of the knowledge gained from laboratory findings is essential to address the clinical significance of p38 MAPK signaling pathways. The goal of this review is to provide an overview on recent progress made in defining the functions of p38 MAPK pathways with respect to solid tumor biology and generate testable hypothesis with respect to the role of p38 MAPK as an attractive target for intervention of solid tumors.

Entities:  

Keywords:  mitogen-activated protein kinase (MAPK); p38 signaling pathway; solid tumors

Year:  2013        PMID: 24349632      PMCID: PMC3863344          DOI: 10.1177/1947601913507951

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  273 in total

Review 1.  Antioxidants and oxidants regulated signal transduction pathways.

Authors:  Edward D Owuor; Ah-Ng Tony Kong
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

2.  A subtle change in p38 MAPK activity is sufficient to suppress in vivo tumorigenesis.

Authors:  Oleg Timofeev; Ting Yi Lee; Dmitry V Bulavin
Journal:  Cell Cycle       Date:  2005-01-30       Impact factor: 4.534

Review 3.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

4.  Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation.

Authors:  Jayoung Kim; Rosalyn M Adam; Michael R Freeman
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

5.  Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis.

Authors:  M Verheij; R Bose; X H Lin; B Yao; W D Jarvis; S Grant; M J Birrer; E Szabo; L I Zon; J M Kyriakis; A Haimovitz-Friedman; Z Fuks; R N Kolesnick
Journal:  Nature       Date:  1996-03-07       Impact factor: 49.962

6.  Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells.

Authors:  Qiwei Han; Jay Leng; Dafang Bian; Chitladda Mahanivong; Kevin A Carpenter; Zhixing K Pan; Jiahuai Han; Shuang Huang
Journal:  J Biol Chem       Date:  2002-10-10       Impact factor: 5.157

7.  Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine.

Authors:  J E Nutt; G C Durkan; J K Mellon; J Lunec
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

8.  TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway.

Authors:  Giichi Takaesu; Rama M Surabhi; Kyu-Jin Park; Jun Ninomiya-Tsuji; Kunihiro Matsumoto; Richard B Gaynor
Journal:  J Mol Biol       Date:  2003-02-07       Impact factor: 5.469

9.  ASK1 mediates apoptotic cell death induced by genotoxic stress.

Authors:  Z Chen; H Seimiya; M Naito; T Mashima; A Kizaki; S Dan; M Imaizumi; H Ichijo; K Miyazono; T Tsuruo
Journal:  Oncogene       Date:  1999-01-07       Impact factor: 9.867

10.  Urinary bladder lesions induced by persistent chronic low-dose ionizing radiation.

Authors:  Alina Romanenko; Keiichirou Morimura; Hideki Wanibuchi; Min Wei; Wadim Zaparin; Wladimir Vinnichenko; Anna Kinoshita; Alexander Vozianov; Shoji Fukushima
Journal:  Cancer Sci       Date:  2003-04       Impact factor: 6.716

View more
  172 in total

1.  The human chemokine receptor CCRL2 suppresses chemotaxis and invasion by blocking CCL2-induced phosphorylation of p38 MAPK in human breast cancer cells.

Authors:  Lei-Ping Wang; Jun Cao; Jian Zhang; Bi-Yun Wang; Xi-Chun Hu; Zhi-Min Shao; Zhong-Hua Wang; Zhou-Luo Ou
Journal:  Med Oncol       Date:  2015-10-20       Impact factor: 3.064

2.  Discovery and Characterization of a Biologically Active Non-ATP-Competitive p38 MAP Kinase Inhibitor.

Authors:  Brice A P Wilson; Muhammad S Alam; Tad Guszczynski; Michal Jakob; Shilpa R Shenoy; Carter A Mitchell; Ekaterina I Goncharova; Jason R Evans; Peter Wipf; Gang Liu; Jonathan D Ashwell; Barry R O'Keefe
Journal:  J Biomol Screen       Date:  2015-11-04

3.  MAPKs' status at early stages of renal carcinogenesis and tumors induced by ferric nitrilotriacetate.

Authors:  Francisco A Aguilar-Alonso; José D Solano; Chabetty Y Vargas-Olvera; Ignacio Pacheco-Bernal; Telma O Pariente-Pérez; María Elena Ibarra-Rubio
Journal:  Mol Cell Biochem       Date:  2015-02-28       Impact factor: 3.396

4.  Enhanced expression of long noncoding RNA CARLo-5 is associated with the development of gastric cancer.

Authors:  Yan Zhang; Mingzhe Ma; Weiyong Liu; Wenping Ding; Honggang Yu
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

5.  Differential effects of p38 MAP kinase inhibitors SB203580 and SB202190 on growth and migration of human MDA-MB-231 cancer cell line.

Authors:  Şükrü Aydın Düzgün; Azmi Yerlikaya; Sezgin Zeren; Zülfü Bayhan; Emrah Okur; İhsan Boyacı
Journal:  Cytotechnology       Date:  2017-04-09       Impact factor: 2.058

6.  Quantitative method for in vitro matrigel invasiveness measurement through image analysis software.

Authors:  Gabriel Gallo-Oller; Juan A Rey; Javier Dotor; Javier S Castresana
Journal:  Mol Biol Rep       Date:  2014-07-03       Impact factor: 2.316

7.  Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss.

Authors:  Bhavna Murali; Qihao Ren; Xianmin Luo; Douglas V Faget; Chun Wang; Radia Marie Johnson; Tina Gruosso; Kevin C Flanagan; Yujie Fu; Kathleen Leahy; Elise Alspach; Xinming Su; Michael H Ross; Barry Burnette; Katherine N Weilbaecher; Morag Park; Gabriel Mbalaviele; Joseph B Monahan; Sheila A Stewart
Journal:  Cancer Res       Date:  2018-08-09       Impact factor: 12.701

8.  Treatment with MQA, a Derivative of Caffeoylquinic Acid, Provides Neuroprotective Effects against Cerebral Ischemia Through Suppression of the p38 Pathway and Oxidative Stress in Rats.

Authors:  Long Chen; Dan-Ni Liu; Yu Wang; Xue-Ying Liu; Shuai Han; Ke Zhang; Guo-Yu Li; Xing Tian; Hang-Yu Wang; Jin-Hui Wang
Journal:  J Mol Neurosci       Date:  2019-02-08       Impact factor: 3.444

9.  Inhibiting the P2X4 Receptor Suppresses Prostate Cancer Growth In Vitro and In Vivo, Suggesting a Potential Clinical Target.

Authors:  Jiepei He; Yuhan Zhou; Hector M Arredondo Carrera; Alexandria Sprules; Ramona Neagu; Sayyed Amin Zarkesh; Colby Eaton; Jian Luo; Alison Gartland; Ning Wang
Journal:  Cells       Date:  2020-11-20       Impact factor: 6.600

10.  Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.

Authors:  Ulf Lützen; Yi Zhao; Katja Lucht; Maaz Zuhayra; Marlies Marx; Ingolf Cascorbi; Juraj Culman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-23       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.